Growth finance for agencies: how to productise the offering for healthcare and life sciences

This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install growth finance has to reflect that reality from day one.

Growth finance is one of the highest-margin offerings an agency can add in 2026. It is running growth as a portfolio with a return-on-invested-capital lens, and clients will pay a premium for the discipline they cannot install themselves.

Productise around outcome, not activity. Sell CAC payback and gross margin moving to a defined level in a defined window, not a monthly retainer of vague ops.

Delivery pod: one strategist, one operator, one editor. Fewer people than that risks quality; more than that dilutes margin.

The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Growth finance is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.

Onboarding takes two weeks: diagnosis, list build, trigger definition, kill criteria. Do not ship anything live before the diagnosis is signed off.

Pricing: outcome-linked base plus a monthly ops fee. The base rewards results; the ops fee funds the delivery pod.

Client failure mode: optimising for growth rate at any cost. Write it into the engagement letter as a shared risk, not something you absorb quietly.

The agencies making the most from growth finance are the ones with the tightest playbook. Documented, versioned, and improved every quarter.

Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing growth finance properly rather than half-heartedly across three vendors.